Darolutamide Stands Out in the Pool of 2nd Generation Antiandrogen Therapies
Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Eleni Efstathiou, MD, PhD, an oncology specialist at the University of Texas MD Anderson Cancer Center provides background on the ARAMIS trial of darolutamide (Nubeqa) compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Back in 2006, agents like abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) were being developed, oncologists at the time believed that the field was becoming saturated with antiandrogentherapies. Efstathiou says, that what is interesting about darolutamide, is that it has the ability to cross the blood-brain barrier. This sets darolutamide apart from enzalutamide and apalutamide, especially, because the mechanism of action for these 2 agents are almost identical.
Overall, the profile of darolutamide makes it ideal to help improve quality of life in patients with nmCRPC, Efstathiou explains.
Subcutaneous Daratumumab Significantly Delays Progression in Smoldering Myeloma
December 9th 2024Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS compared with active monitoring in patients with smoldering multiple myeloma.
Read More
